GERD
Conditions
Brief summary
Gastroesophageal reflux disease (GERD) is a condition caused by the reflux of stomach contents into the esophagus, presenting with typical symptoms such as heartburn and acid regurgitation. GERD is a chronic condition that affects quality of life, and patients with this condition are known to have a lower quality of life compared to healthy individuals. In particular, nocturnal heartburn can lead to sleep deprivation and affect daily life, as well as overall quality of life. This study aims to evaluate the efficacy of alleviating nocturnal heartburn symptoms in patients with erosive reflux disease (ERD).
Detailed description
This multicenter, double-blind, randomized, active-controlled Phase 4 study aims to exploratorily evaluate the comparative effects and safety of zastaprazan 20 mg and esomeprazole 40 mg in subjects with gastroesophageal reflux disease.
Interventions
DRUGZastaprazan
Participants in this arm will receive zastaprazan. This group serves as the experimental treatment group exploratorily evaluating drug for GERD.
DRUGEsomeprazole
Participants in this arm will receive esomeprazole. This group serves as the active comparator treatment group exploratorily evaluating drug for GERD.
Sponsors
Incheon St.Mary's Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Korean adults aged 19 years or older as of the date of written consent 2. Those diagnosed with erosive gastroesophageal reflux disease based on upper gastrointestinal endoscopy (EGD) 3. Those who reported nighttime heartburn for more than 3 months at the time of screening (Visit 1) 4. Those who voluntarily decided to participate and provide written informed consent
Exclusion criteria
1. Those who cannot undergo upper gastrointestinal endoscopy (EGD) 2. Individuals with a history of drug or alcohol abuse (within the past year) 3. Individuals who have received other investigational products within one month prior to the screening visit (Visit 1) 4. In addition to the above, individuals with clinically significant findings that the investigator deems medically inappropriate for the present study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of participants without sleep disturbance related to nighttime heartburn during the last 7 days | Week 2 | This measure is based on participant-reported information collected by subject diary during the study and reflects whether sleep disturbance related to heartburn was noted over the period evaluated. Symptom severity ranges from 0 to 4, with higher scores indicating worse sleep disturbance. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of participants without sleep disturbance related to nighttime heartburn during the last 7 days | Week 4 | This measure is based on participant-reported information collected by subject diary during the study and reflects whether sleep disturbance related to heartburn was noted over the period evaluated. Symptom severity ranges from 0 to 4, with higher scores indicating worse sleep disturbance. |
| Mean change from baseline in Gastroesophageal Reflux Disease-Health Related Quality of Life (GERD-HRQL) score | Baseline, Week 2, Week 4 | The change from baseline in GERD-HRQL scores, evaluated at Weeks 2 and 4 during the treatment period. The GERD-HRQL uses item scores ranging from 0 to 5, with higher scores indicating more severe symptoms. |
| Mean change from baseline in Gastrointestinal Symptom Rating Scale (GSRS) score | Baseline, Week 2, Week 4 | The GSRS assesses gastrointestinal symptoms across multiple domains, with each item scored on a 1 to 7 scale, where higher scores indicate more severe symptoms. |
| Change from baseline in Gastroesophageal Reflux Disease Questionnaire (GerdQ) score | Baseline, Week 2, Week 4 | The GerdQ evaluates symptoms using ordinal item scores; for heartburn and acid regurgitation items, higher scores indicate more frequent symptoms; each item is scored on a 0 to 3 scale based on symptom frequency over the previous week, with reverse scoring applied to upper stomach pain and nausea items. |
Countries
South Korea
Contacts
Primary ContactByung-Wook Kim
Outcome results
None listed